RT info:eu-repo/semantics/article
T1 Intrapleural mitoxantrone for the palliative treatment of malignant pleural effusions
A1 Morales González, Manuel José
A1 Expósito, María del Carmen
A2 Medicina InternaDermatología y Psiquiatría
K1 Intrapleural mitoxantrone
K1 pleural effusions
AB Pleural effusions are common in patients with cancerand cause a significant morbidity. The optimal treatment for the control of pleural effusions is not defined.In patients with drug-sensitive tumors (e.g. breast cancer, lymphomas, small-cell lung cancer) systemic chemotherapy is the treatment of choice. For patients withother solid tumors and in recurrences despite systemicchemotherapy, the optimal treatment consists of thoracostomy-tube drainage with the instillation of a sclerosing agent [3]. Several agents are used to achieve pleuorodesis: tetracycline, bleomycin, quinacrine, nitrogenmustard, doxorubicin, mitoxantrone and talc [7]. Mitoxantrone shows a steep dose/effect relationship fordifferent human tumor cell lines in vitro, and is a drugwell tolerated locally [2]. Whilst the usual dose of mitoxantrone for intrapleural therapy is 30 mg [6], we increased the dose to 40 mg.
YR 1995
FD 1995
LK http://riull.ull.es/xmlui/handle/915/40030
UL http://riull.ull.es/xmlui/handle/915/40030
LA en
DS Repositorio institucional de la Universidad de La Laguna
RD 29-nov-2024